Oramed Pharmaceuticals Inc.
ORMP
$2.12
-$0.05-2.30%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -36.93% | 8.11% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -61.71% | 80.81% | |||
| Operating Income | 44.69% | -25.17% | |||
| Income Before Tax | 286.09% | 27.85% | |||
| Income Tax Expenses | -121.58% | 40.38% | |||
| Earnings from Continuing Operations | 273.51% | 25.07% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 273.88% | 25.00% | |||
| EBIT | 44.69% | -25.17% | |||
| EBITDA | 44.99% | -25.42% | |||
| EPS Basic | 271.68% | 25.99% | |||
| Normalized Basic EPS | 57.09% | -44.60% | |||
| EPS Diluted | 263.16% | 27.98% | |||
| Normalized Diluted EPS | 57.85% | -44.60% | |||
| Average Basic Shares Outstanding | 1.25% | 1.38% | |||
| Average Diluted Shares Outstanding | 3.35% | 1.38% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||